Federal Trade Commission v. Raladam Co.

Background

The Federal Trade Commission brought a complaint against a company that made and sold a marketed "obesity cure" across state lines. The product’s ads claimed scientific research, safety, and effectiveness, and the ingredient list included desiccated thyroid. After hearings the Commission found the product unsafe for general use without medical supervision and issued a cease-and-desist order aimed at stopping the company’s advertising claims; the court of appeals reversed that order and the case came to this Court limited to the question of the Commission’s power.

Reasoning

The Court focused on whether the Commission had authority under the Trade Commission Act to stop the company’s advertising. The law allows action only when unfair methods are used in competition and when a Commission proceeding would serve the public interest. The Court assumed unfairness and public interest but required proof that the challenged practices affected present or potential competitors. The Commission’s record did not prove that other sellers were actually or clearly threatened with substantial injury; evidence of competitors was vague or came from non-competing medical sources. Because the existence of substantial competition was unproven, the Commission lacked jurisdiction to issue a final cease-and-desist order, and the lower court’s reversal was affirmed.

Real world impact

The decision requires the FTC to show that an unfair practice injures or threatens real competition before issuing a stopping order. Misleading health advertising by itself, without proof that rival businesses were harmed or threatened, may not suffice to support a §5 enforcement order. Other laws, like misbranding statutes, may address safety or labeling but are not administered by the Commission.